Net Loss per Share

12 Months Ended

Dec. 31, 2020

7. Net Loss per Share

Diluted EPS for the year ended December 31, 2019 included a numerator adjustment to remove the gain related to the change in fair value of derivative liabilities $0.9 million, net of interest. Additionally, diluted EPS for the year ended December 31, 2019 included an adjustment to the weighted-average shares outstanding to appropriately weigh the shares issued for the Synthetic Genomics asset acquisition discussed in Note 12.


	Year Ended
	December 31,
	2020		2019
Basic and diluted net loss per share calculation:
Net loss, basic	$	(22,181,000)	$	(19,479,000)
Change in fair value of derivative liabilities, net of interest		—		(938,000)
Net loss, diluted		(22,181,000)		(20,417,000)
Weighted average shares outstanding, basic		16,415,012		7,827,197
Net loss per share, basic	$	(1.35)	$	(2.49)
Weighted average shares outstanding, diluted		16,415,012		8,009,909
Net loss per share, diluted	$	(1.35)	$	(2.55)

The following outstanding securities at December 31, 2020 and 2019 have been excluded from the computation of diluted weighted average shares outstanding for the years ended December 31, 2020 and 2019, as they would have been anti-dilutive:


	Year Ended
	December 31,
	2020	2019
Options	1,668,926	1,275,380
Restricted stock awards	322,756	343,493
Warrants	10,547,618	1,854,007
Total	12,539,300	3,472,880